Abstract
Purpose
We investigated the usefulness of the modified RENAL nephrometry (mRN) scoring system for predicting post-cryotherapy renal function in patients with T1a renal mass.
Patients and Methods
A total of 75 patients with a T1a renal mass were enrolled. The mRN score was determined based on the tumor size, the tumor’s exophytic/endophytic properties, the tumor’s nearness to the collecting system, and the anterior/posterior location of the kidney. The change in the estimated glomerular filtration rate (ΔeGFR) was calculated as follows: ΔeGFR = 100 × ([pretreatment eGFR − eGFR at 6 months after cryotherapy]/pretreatment eGFR). Based on the ΔeGFR results, we classified the patients into two groups: a preserved renal function group (ΔeGFR < 10%) and an impaired renal function group (ΔeGFR ≥ 10%). We then analyzed the relationships between the mRN score and ΔeGFR and between the mRN score and the chronic kidney disease (CKD) stage.
Results
The mean ΔeGFR for all patients was 5.5%. The mRN scores of the preserved renal function group (5.8 ± 0.3) were significantly lower than those of the impaired group (7.4 ± 0.3) (p < 0.001). When the mRN score cutoff value was set at 7 points, the mRN had 67.7% sensitivity, 72.7% specificity, 61.8% positive predictive value (PPV), 76.1% negative predictive value (NPV), and 70.7% accuracy for predicting impaired renal function. For predicting a deterioration of CKD stage, the mRN had 92.9% sensitivity, 67.2% specificity, 39.4% PPV, 97.6% NPV, and 72% accuracy.
Conclusion
Our newly proposed modified RENAL nephrometry score was suggested to be useful for predicting renal function after renal cryotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182:1271–9.
Georgiades CS, Rodriguez R. Efficacy and safety of percutaneous cryoablation for stage 1A/B renal cell carcinoma: results of a prospective, single-arm, 5-year study. Cardiovasc Interv Radiol. 2014;37:1494–9.
Buy X, Lang H, Garnon J, Sauleau E, Roy C, Gangi A. Percutaneous renal cryoablation: prospective experience treating 120 consecutive tumors. AJR Am J Roentgenol. 2013;201:1353–61.
Aoun HD, Littrup PJ, Jaber M, Memon F, Adam B, Krycia M, Prus M, et al. Percutaneous cryoablation of renal tumors: is it time for a new paradigm shift? J Vasc Interv Radiol. 2017;28:1363–70.
Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182:844–53.
Kopp RP, Liss MA, Mehrazin R, Wang S, Lee HJ, Jabaji R, Mirheydar HS, et al. Analysis of renal functional outcomes after radical or partial nephrectomy for renal masses >/=7 cm using the RENAL score. Urology. 2015;86:312–9.
Gahan JC, Richter MD, Seideman CA, Trimmer C, Chan D, Weaver M, Olweny EO, et al. The performance of a modified RENAL nephrometry score in predicting renal mass radiofrequency ablation success. Urology. 2015;85:125–9.
Yamanaka T, Yamakado K, Yamada T, Fujimori M, Takaki H, Nakatsuka A, Sakuma H, et al. CT-guided percutaneous cryoablation in renal cell carcinoma: factors affecting local tumor control. J Vasc Interv Radiol. 2015;26:1147–53.
Global KDI. Kdigo 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1.
Park SY, Park BK, Kim CK. Thermal ablation in renal cell carcinoma: what affects renal function? Int J Hyperth. 2012;28:729–34.
Campbell SC, Novick AC, Streem SB, Klein E, Licht M. Complications of nephron sparing surgery for renal tumors. J Urol. 1994;151:1177–80.
Raman JD, Jafri SM, Qi D. Kidney function outcomes following thermal ablation of small renal masses. World J Nephrol. 2016;5:283–7.
Weisbrod AJ, Atwell TD, Frank I, Callstrom MR, Farrell MA, Mandrekar JN, Charboneau JW. Percutaneous cryoablation of masses in a solitary kidney. AJR Am J Roentgenol. 2010;194:1620–5.
Turna B, Kaouk JH, Frota R, Stein RJ, Kamoi K, Gill IS, Novick AC. Minimally invasive nephron sparing management for renal tumors in solitary kidneys. J Urol. 2009;182:2150–7.
Wuerzner G, Firsov D, Bonny O. Circadian glomerular function: from physiology to molecular and therapeutical aspects. Nephrol Dial Transplant. 2014;29:1475–80.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
Informed Consent
This study has obtained IRB approval from Kyushu University, and the need for informed consent was waived.
Consent for Publication
For this type of study consent for publication is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Asayama, Y., Nishie, A., Ushijima, Y. et al. Usefulness of a Pretreatment CT-Based Modified RENAL Nephrometry Score in Predicting Renal Function After Cryotherapy for T1a Renal Mass. Cardiovasc Intervent Radiol 42, 1128–1134 (2019). https://doi.org/10.1007/s00270-019-02238-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-019-02238-1